China Healthwise Holdings Limited has announced its unaudited interim results for the six months ended 30 June 2025. The Group reported a total revenue of HK$51.06 million, a decrease from HK$60.93 million in the same period of 2024. Revenue from the sale of Chinese health products was HK$50.98 million, down from HK$60.43 million in the previous year. The money lending business generated HK$0.32 million, a decline from HK$0.61 million. The segment for investment in financial instruments recorded a loss of HK$0.24 million, compared to a loss of HK$0.11 million the year before. The Group's segment profit before income tax totaled HK$7.84 million, contrasting with a segment loss of HK$4.40 million from Chinese health products, a profit of HK$0.87 million from the money lending business, and a profit of HK$11.37 million from investments in financial instruments. No outlook or guidance updates were provided in the announcement.